Valerio Therapeutics
Develops precision-targeted antibody therapies for complex and underserved diseases
Highlights
- New on EvolcAdded 2026-10-30
About Valerio Therapeutics
Valerio Therapeutics develops therapeutic candidates using its V-Body platform, which combines synthetic single-domain antibody libraries, target identification, antibody engineering and drug-conjugate chemistry. Its research aims to advance candidates from preclinical development toward clinical proof of concept.
The company advances candidates toward development milestones and pursues co-development, out-licensing and research collaborations. Its headquarters are in Villejuif, France.
Product: A discovery and therapeutic development platform for single-domain antibody medicines and drug conjugates.
Jobs at Valerio Therapeutics
Leadership
- Gilles Besin · Chief Executive OfficerSource: company website
- Wael Jdey · Chief Technology OfficerSource: company website
More biotech & pharma companies
Valneva
Develops, manufactures and commercializes preventive vaccines for infectious diseases for healthcare professionals and travelersNew on EvolcSalary transparentVaxinano
Vaccine and antigen delivery platform for veterinary and human infectious diseases, including zoonosesNew on EvolcVect-Horus
Develops targeting technology to transport therapeutic and imaging agents across the blood–brain barrier for pharma and biotech partnersNew on EvolcVivet Therapeutics
Clinical-stage gene therapy developer for rare inherited liver metabolic diseases, based in ParisNew on EvolcWhitelab Genomics
AI and computational biology tools for biotech and pharmaceutical teams developing genomic medicinesNew on EvolcXenothera
Develops glyco-humanized antibody treatments for patients with a range of therapeutic needsNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Cloudflare
- Complianz
- WordPress
- jQuery